Endosense brings in €25mm through its Series B venture round
Executive Summary
Endosense (catheter ablation for cardiac arrhythmias) has raised €25mm ($36mm) through the closing of its Series B venture round. Edmond de Rothschild Investment Partners (EdRIP) led the financing and was joined by NeoMed, GIMV, VI Partners, Sectoral Asset Management, Ysios Capital Partners, and Initiative Capital Romandie. Endosense will use the money for European commercialization (it gained the CE Mark four months ago) and a US PMA study of its TactiCath ablation catheter. Representatives from EdRIP, GIMV, and VI will take seats on the company's board.
Deal Industry
- Medical Devices
-
Medical Devices
-
Surgical Equipment & Devices
- Minimally or Less Invasive
-
Surgical Equipment & Devices
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice